# Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations

> **NCT00943943** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 33 (actual)

## Conditions studied

- Acute Myelogenous Leukemia
- Leukemia

## Interventions

- **DRUG:** G-CSF
- **DRUG:** Plerixafor
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT00943943
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-29
- **Primary completion:** 2017-03-23
- **Final completion:** 2017-03-23
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2017-03-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00943943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00943943, "Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00943943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*